Trial Profile
A Phase 1 Window of Opportunity Study Investigating the Pharmacodynamic Biomarker Effects of AZD2014 (an mTOR1/2 Inhibitor) Given Prior to Radical Prostatectomy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vistusertib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms CaNCaP02
- 13 Jul 2018 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 16 Jan 2018 Planned End Date changed from 1 Oct 2017 to 1 Feb 2018.